secwatch.observer — SEC 8-K summary
======================================

Issuer:     MoonLake Immunotherapeutics (MLTX)
CIK:        0001821586
Form:       8-K
Filed at:   2023-09-01T23:59:59+00:00
Accession:  0001213900-23-073296
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

MoonLake raises CEO, CSO, CFO salaries and bonuses citing MIRA trial success
----------------------------------------------------------------------------

- New annual base salaries July 1, 2023: CEO Jorge Santos da Silva CHF 600k (was CHF 450k), CSO Kristian Reich CHF 600k (was CHF 450k), CFO Matthias Bodenstedt CHF 475k (was CHF 325k).
- Target bonuses raised to 55% of salary for CEO and CSO, 50% for CFO (previously 50%, 50%, 40% respectively).
- Board cites positive Phase 2 MIRA trial results and peer benchmarking as rationale for adjustments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821586/000121390023073296/0001213900-23-073296-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821586/000121390023073296/ea184508-8k_moonlake.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-073296

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer